News | June 18, 2022
Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation
Both manufacturing facilities are based out of Benguluru, India
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
Includes thermostabilized Ebola vaccines
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
Subscribe To Our Newsletter & Stay Updated
